Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives $11.00 Average Target Price from Analysts

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) have been given an average rating of "Buy" by the six research firms that are currently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $11.00.

Several analysts have recently issued reports on EPRX shares. Canaccord Genuity Group started coverage on Eupraxia Pharmaceuticals in a report on Monday, June 16th. They set a "speculative buy" rating on the stock. HC Wainwright started coverage on Eupraxia Pharmaceuticals in a report on Thursday, June 26th. They set a "buy" rating and a $12.00 target price on the stock. Finally, Cantor Fitzgerald started coverage on Eupraxia Pharmaceuticals in a report on Thursday. They set an "overweight" rating and a $11.00 target price on the stock.

Eupraxia Pharmaceuticals Price Performance

NASDAQ EPRX traded down $0.05 on Thursday, reaching $5.49. The stock had a trading volume of 31,871 shares, compared to its average volume of 11,357. The firm has a fifty day moving average of $4.63 and a two-hundred day moving average of $3.89. Eupraxia Pharmaceuticals has a 1-year low of $2.20 and a 1-year high of $6.20. The company has a market cap of $197.42 million, a P/E ratio of -7.22 and a beta of 1.55.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). Research analysts predict that Eupraxia Pharmaceuticals will post -0.67 EPS for the current fiscal year.

Institutional Trading of Eupraxia Pharmaceuticals

Large investors have recently bought and sold shares of the business. Millennium Management LLC bought a new position in Eupraxia Pharmaceuticals in the fourth quarter valued at about $31,000. Raymond James Financial Inc. bought a new position in Eupraxia Pharmaceuticals in the fourth quarter valued at about $37,000. Bank of Montreal Can raised its position in Eupraxia Pharmaceuticals by 15.2% in the fourth quarter. Bank of Montreal Can now owns 56,750 shares of the company's stock valued at $178,000 after purchasing an additional 7,500 shares during the last quarter. Royal Bank of Canada raised its position in Eupraxia Pharmaceuticals by 21.1% in the first quarter. Royal Bank of Canada now owns 342,828 shares of the company's stock valued at $1,125,000 after purchasing an additional 59,683 shares during the last quarter. Finally, Scotia Capital Inc. raised its position in Eupraxia Pharmaceuticals by 11.6% in the first quarter. Scotia Capital Inc. now owns 1,552,679 shares of the company's stock valued at $5,072,000 after purchasing an additional 160,960 shares during the last quarter.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.